Le Lézard
Classified in: Health, Science and technology
Subject: Funding

CinRx Pharma Announces Additional $73 Million Financing


CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million. Participants in the round include prior investors comprised of industry insiders and high-net-worth individuals. To date, CinRx has launched five companies ("CinCos") focused primarily on cardiovascular, metabolic and gastrointestinal conditions. In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies. CinRx plans to use the funds to advance development of its existing portfolio programs and assets to expand in key areas of high unmet medical need.

"Our early financings totaling $103 million supported the construction and progression of our seven-company portfolio. Notably, this included the formation, advancement and exit of CinCor Pharma ahead of its $1.8 billion acquisition, underscoring the success of our incredibly effective team and validation of our efficient business model," said Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma. "With this infusion of capital, we will continue rapid advancement of existing programs and replicate our proven asset selection process to identify and accelerate more promising new programs with high potential to impact patients' quality of life."

CinRx's portfolio of CinCos are managed by a lean team of scientific, technical and drug development experts with decades of experience treating patients and supporting thousands of clinical development programs. Each CinCo was created through a rigorous asset selection process to identify novel therapies with the potential to address significant unmet medical needs and meaningfully reduce disease burden for patients.

About CinRx Pharma:

CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx's approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx's central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients' quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.

For more information, please visit www.CinRx.com or follow the company on X and LinkedIn.


These press releases may also interest you

at 14:41
Product: Fried Falafel with Tahini Sauce Issue: Food - Allergen - Peanut Distribution:       Alberta                           Newfoundland and Labrador                           Ontario See the affected products and product photos for this recall...

at 11:15
Exelixis, Inc. today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell...

at 09:00
For children with high threshold peanut allergy, oral immunotherapy using store-bought and home-measured peanut products provided significantly higher rates of desensitization compared to peanut avoiders, according to new research being presented at...

at 09:00
LifeNet Health proudly announces the launch of OraGen®, the first viable dental bone allograft comprised of cryopreserved corticocancellous bone containing endogenous lineage-committed bone cells combined with demineralized bone matrix. This unique...

at 08:00
The Ontario Health Coalition is holding press conferences with patients who have been charged for cataract surgeries or manipulated into paying for medically unnecessary add-ons in private clinics. The Coalition is calling on all political parties to...

14 fév 2025
Report with market evolution powered by AI - The global gender reassignment surgery market  size is estimated to grow by USD 374.2 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of over 11.2%  during the...



News published on and distributed by: